Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1977 1
1982 3
1983 4
1984 1
1985 5
1986 11
1987 8
1988 10
1989 29
1990 30
1991 28
1992 35
1993 19
1994 27
1995 36
1996 46
1997 72
1998 49
1999 60
2000 89
2001 81
2002 87
2003 101
2004 116
2005 152
2006 133
2007 160
2008 173
2009 179
2010 179
2011 219
2012 218
2013 230
2014 281
2015 328
2016 342
2017 316
2018 323
2019 441
2020 445
2021 539
2022 520
2023 509
2024 255

Text availability

Article attribute

Article type

Publication date

Search Results

6,208 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Alzheimer disease 11"
Page 1
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease.
Khan S, Barve KH, Kumar MS. Khan S, et al. Curr Neuropharmacol. 2020;18(11):1106-1125. doi: 10.2174/1570159X18666200528142429. Curr Neuropharmacol. 2020. PMID: 32484110 Free PMC article. Review.
OBJECTIVE: Accurate diagnosis at an early stage is the need of the hour for initiation of therapy. The cause for most Alzheimer's cases still remains unknown except where genetic distinctions have been observed. Thus, a standard drug regimen ensues in every Alzhe …
OBJECTIVE: Accurate diagnosis at an early stage is the need of the hour for initiation of therapy. The cause for most Alzheimer's cas …
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
IMPORTANCE: There are limited efficacious treatments for Alzheimer disease. OBJECTIVE: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. ...MAIN OUTCOMES AND MEASURES: The primary outcome was change in integrated …
IMPORTANCE: There are limited efficacious treatments for Alzheimer disease. OBJECTIVE: To assess efficacy and adverse events o …
Physiotherapy intervention in Alzheimer's disease: systematic review and meta-analysis.
Zhu XC, Yu Y, Wang HF, Jiang T, Cao L, Wang C, Wang J, Tan CC, Meng XF, Tan L, Yu JT. Zhu XC, et al. J Alzheimers Dis. 2015;44(1):163-74. doi: 10.3233/JAD-141377. J Alzheimers Dis. 2015. PMID: 25201787 Review.
BACKGROUND: Many studies reported that physiotherapy interventions are available to treat Alzheimer's disease (AD), but the efficacy remains uncertain. OBJECTIVE: To evaluate the effectiveness of physiotherapy intervention on AD. ...Other outcomes are also significa …
BACKGROUND: Many studies reported that physiotherapy interventions are available to treat Alzheimer's disease (AD), but the ef …
Peripheral and central immune system crosstalk in Alzheimer disease - a research prospectus.
Bettcher BM, Tansey MG, Dorothée G, Heneka MT. Bettcher BM, et al. Nat Rev Neurol. 2021 Nov;17(11):689-701. doi: 10.1038/s41582-021-00549-x. Epub 2021 Sep 14. Nat Rev Neurol. 2021. PMID: 34522039 Free PMC article. Review.
Dysregulation of the immune system is a cardinal feature of Alzheimer disease (AD), and a considerable body of evidence indicates pathological alterations in central and peripheral immune responses that change over time. ...To guide the prospectus, we begin with an …
Dysregulation of the immune system is a cardinal feature of Alzheimer disease (AD), and a considerable body of evidence indica …
Sleep duration, genetic susceptibility, and Alzheimer's disease: a longitudinal UK Biobank-based study.
Yuan S, Ma W, Yang R, Xu F, Han D, Huang T, Peng M, Xu A, Lyu J. Yuan S, et al. BMC Geriatr. 2022 Aug 2;22(1):638. doi: 10.1186/s12877-022-03298-8. BMC Geriatr. 2022. PMID: 35918656 Free PMC article.
BACKGROUND: Alzheimer's disease (AD) is the most frequently occurring type of dementia. ...No statistically significant interaction was identified between sleep duration and the AD-GRS (Alzheimer's disease genetic risk score, P for interaction = …
BACKGROUND: Alzheimer's disease (AD) is the most frequently occurring type of dementia. ...No statistically significant intera …
Development and validation of an interpretable deep learning framework for Alzheimer's disease classification.
Qiu S, Joshi PS, Miller MI, Xue C, Zhou X, Karjadi C, Chang GH, Joshi AS, Dwyer B, Zhu S, Kaku M, Zhou Y, Alderazi YJ, Swaminathan A, Kedar S, Saint-Hilaire MH, Auerbach SH, Yuan J, Sartor EA, Au R, Kolachalama VB. Qiu S, et al. Brain. 2020 Jun 1;143(6):1920-1933. doi: 10.1093/brain/awaa137. Brain. 2020. PMID: 32357201 Free PMC article.
Here we report an interpretable deep learning strategy that delineates unique Alzheimer's disease signatures from multimodal inputs of MRI, age, gender, and Mini-Mental State Examination score. ...The model was trained using clinically diagnosed Alzheimer …
Here we report an interpretable deep learning strategy that delineates unique Alzheimer's disease signatures from multimodal i …
Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study.
Florian H, Wang D, Arnold SE, Boada M, Guo Q, Jin Z, Zheng H, Fisseha N, Kalluri HV, Rendenbach-Mueller B, Budur K, Gold M. Florian H, et al. Brain. 2023 Jun 1;146(6):2275-2284. doi: 10.1093/brain/awad024. Brain. 2023. PMID: 36730056 Free PMC article. Clinical Trial.
Tau accumulation in patients with Alzheimer's disease tracks closely with cognitive decline and plays a role in the later stages of disease progression. ...Tilavonemab was generally well tolerated but did not demonstrate efficacy in treating patients with ear …
Tau accumulation in patients with Alzheimer's disease tracks closely with cognitive decline and plays a role in the later stag …
Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Villemagne VL, et al. Lancet Neurol. 2013 Apr;12(4):357-67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8. Lancet Neurol. 2013. PMID: 23477989
BACKGROUND: Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly from a preclinical phase into a fully expressed clinical syndrome. ...Abeta deposition was estimated to take 19.2 (95% CI 16.8-22.5) years in an almost linear fashion-with a mean …
BACKGROUND: Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly from a preclinical phase into a fully e …
Gait in Cerebral Amyloid Angiopathy.
Sharma B, Gee M, Nelles K, Cox E, Irving E, Saad F, Yuan J, McCreary CR, Ismail Z, Camicioli R, Smith EE. Sharma B, et al. J Am Heart Assoc. 2022 Oct 4;11(19):e025886. doi: 10.1161/JAHA.121.025886. Epub 2022 Sep 21. J Am Heart Assoc. 2022. PMID: 36129041 Free PMC article.
Participants were patients with CAA (n=29), Alzheimer disease with mild dementia (n=16), mild cognitive impairment (n=24), and normal elderly controls (n=47). CAA and Alzheimer disease had similarly impaired Rhythm, Pace, and Variability, and higher du …
Participants were patients with CAA (n=29), Alzheimer disease with mild dementia (n=16), mild cognitive impairment (n=24), and …
Cognitive and MRI trajectories for prediction of Alzheimer's disease.
Mofrad SA, Lundervold AJ, Vik A, Lundervold AS. Mofrad SA, et al. Sci Rep. 2021 Jan 22;11(1):2122. doi: 10.1038/s41598-020-78095-7. Sci Rep. 2021. PMID: 33483535 Free PMC article.
The concept of Mild Cognitive Impairment (MCI) is used to describe the early stages of Alzheimer's disease (AD), and identification and treatment before further decline is an important clinical task. ...The results are in-line with findings showing that cognitive ch …
The concept of Mild Cognitive Impairment (MCI) is used to describe the early stages of Alzheimer's disease (AD), and identific …
6,208 results